They could have shown a loss and given no guidance for the next quarter, but instead they went profitable with back to back quarters and gave guidance for fiscal Q3 to be more of the same. Do you recall guidance this far in advance by this company, ever?

They further cut their overhead, banked more cash and gave a shorter timeline for the reexam process to conclude. For those still banking on the patent scenario, which is just about everybody still invested, this sets the table for the next 6 months or so.

The best case scenario would be for the pps to drop even further and then have a positive reexam, Nunchi developments and ongoing recurring licensing revenues, followed by a pps spike. That would present a possibility to buy low again in the face of big developments. The percentage gains from those levels would be impressive, given the outcome noted.

And should there be no pps spike on those developments, then management should pick up as many shares as they can afford with DM back in the saddle, thus increasing shareholder value.